Suppr超能文献

利妥昔单抗作为唯一免疫抑制治疗使C3肾小球病缓解。

Remission of C3 glomerulopathy with rituximab as only immunosuppressive therapy.

作者信息

Giaime Philippe, Daniel Laurent, Burtey Stéphane

出版信息

Clin Nephrol. 2015 Jan;83(1):57-60. doi: 10.5414/CN107945.

Abstract

C3 glomerulopathy (C3GP) is a membranoproliferative glomerulonephritis without immunoglobulin deposits. Activation of the alternative pathway of the complement system is central in its pathogenesis. The presence of a C3 nephritic factor (C3Nef), or deficient factor H or I is associated with C3 GP. The treatment is not codified. Here we describe a case of a Caucasian male with a dense deposit disease (a form of C3GP) revealed by nephritic syndrome. C3Nef was present. We treated him with rituximab as the sole immunosuppressive regimen and obtained a complete remission on proteinuria. The effect was sustained at more than 2 years with only two courses of treatment and an excellent tolerance. Rituximab could be proposed as a treatment of C3GP associated with antibodies interfering with complement alternative pathway.

摘要

C3肾小球病(C3GP)是一种无免疫球蛋白沉积的膜增生性肾小球肾炎。补体系统替代途径的激活在其发病机制中起核心作用。C3肾炎因子(C3Nef)的存在、因子H或I的缺乏与C3GP相关。治疗方法尚无统一规范。在此,我们描述一例白种男性患者,因肾病综合征发现患有致密物沉积病(C3GP的一种形式)。该患者存在C3Nef。我们仅使用利妥昔单抗作为免疫抑制方案对其进行治疗,蛋白尿完全缓解。仅经过两个疗程的治疗,疗效持续超过2年,且耐受性良好。对于与干扰补体替代途径的抗体相关的C3GP,可考虑使用利妥昔单抗进行治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验